Serum homocysteine, folate and vitamin B12 in patients with Paget's disease of bone: The effect of zoledronic acid

Journal of Bone and Mineral Metabolism

Volumn 28, Issue 3, 2010, Pages 314-319

  Polyzos, Stergios A ^a   Anastasilakis, Athanasios D ^b   Efstathiadou, Zoe ^a   Litsas, Ioannis ^a   Kita, Marina ^a   Panagiotou, Athanasios ^a   Papatheodorou, Athanasios ^c   Arsos, Georgios ^d   Moralidis, Efstratios ^d   Barmpalios, Georgios ^a   Zafeiriadou, Efthimia ^a   Triantafillidou, Efthimia ^a   Makrigiannaki, Eleni ^a   Terpos, Evangelos ^c  

^a Ippokration Hospital Thessaloniki   (Greece)

^b 424 General Army Hospital   (Greece)

^c 251 GENERAL AIR FORCE HOSPITAL   (Greece)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Folate; Homocysteine; Paget's disease of bone; Vitamin B12; Zoledronic acid

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE BONE ISOENZYME; CARBOXY TERMINAL TELOPEPTIDE; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; ZOLEDRONIC ACID; 25 HYDROXYERGOCALCIFEROL; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; CALCIFEDIOL; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; IMIDAZOLE DERIVATIVE; ISOENZYME; PEPTIDE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLIC ACID BLOOD LEVEL; HUMAN; MALE; PAGET BONE DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SINGLE DRUG DOSE; VITAMIN BLOOD LEVEL; BLOOD; BODY MASS; BONE REMODELING; BONE TUMOR; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; PAGET SKIN DISEASE; PILOT STUDY; TIME;

25-HYDROXYVITAMIN D 2; AGED; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BODY MASS INDEX; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BONE REMODELING; CALCIFEDIOL; COHORT STUDIES; COLLAGEN TYPE I; DIPHOSPHONATES; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; IMIDAZOLES; ISOENZYMES; MALE; PAGET DISEASE EXTRAMAMMARY; PEPTIDES; PILOT PROJECTS; TIME FACTORS; VITAMIN B 12;

EID: 77956054465     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-009-0131-1     Document Type: Article

References (25)

1. Polyzos SA, Anastasilakis AD, Terpos E (2009) Paget's disease of bone: emphasis on treatment with zoledronic acid Expert Rev Endocrinol Metab 4:423-434
2. Ralston SH, Langston AL, Reid IR (2008) Pathogenesis and management of Paget's disease of bone. Lancet 372:155-163
3. Takata S, Hashimoto J, Nakatsuka K, Yoshimura N, Yoh K, Ohno I, Yabe H, Abe S, Fukunaga M, Terada M, Zamma M, Ralston SH, Morii H, Yoshikawa H (2006) Guidelines for diagnosis and management of Paget's disease of bone in Japan. J Bone Miner Metab 24:359-367
4. Devogelaer JP, Bergmann P, Body JJ, Boutsen Y, Goemaere S, Kaufman JM, Reginster JY, Rozenberg S, Boonen S (2008) Management of patients with Paget's disease: a consensus document of the Belgian Bone Club. Osteoporos Int 19:1109-1117
5. Polyzos SA, Anastasilakis AD, Efstathiadou Z, Kita M, Litsas I, Avramidis A, Arsos G, Moralidis E, Gerou S, Pavlidou V, Papatheodorou A, Terpos E (2009) The effect of zoledronic acid on serum dickkopf-1, osteoprotegerin and RANKL in patients with Paget's disease of bone. Horm Metab Res 41. doi:10.1055/s-0029- 1233491 [Epub ahead of print]
6. Selhub J (2008) Public health significance of elevated homocysteine. Food Nutr Bull 29:116-125
7. Herrmann M, Peter SJ, Umanskaya N, Wagner A, Taban-Shomal O, Widmann T, Colaianni G, Wildemann B, Herrmann W (2007) The role of hyperhomocysteinemia as well as folate, vitamin B(6) and B(12) deficiencies in osteoporosis: a systematic review. Clin Chem Lab Med 45:1621-1632
8. Colina M, La CR, De LF, Trotta F (2008) Paget's disease of bone: a review. Rheumatol Int 28:1069-1075
9. Avramidis A, Polyzos SA, Moralidis E, Arsos G, Efstathiadou Z, Karakatsanis K, Grollios G, Kita M (2008) Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget's disease of bone. J Bone Miner Metab 26:635-641
10. Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D (2005) Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med 353:898-908
11. Polyzos SA, Anastasilakis AD, Terpos E (2009) Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid. Support Care Cancer 17:1329-1330
12. Khan SA, McCloskey EV, Eyres KS, Nakatsuka K, Sirtori P, Orgee J, Coombes G, Kanis JA (1996) Comparison of three intravenous regimens of clodronate in Paget disease of bone. J Bone Miner Res 11:178-182
13. Herrmann M, Tami A, Wildemann B, Wolny M, Wagner A, Schorr H, Taban-Shomal O, Umanskaya N, Ross S, Garcia P, Hubner U, Herrmann W (2009) Hyperhomocysteinemia induces a tissue specific accumulation of homocysteine in bone by collagen binding and adversely affects bone. Bone 44:467-475
14. Koh JM, Lee YS, Kim YS, Kim DJ, Kim HH, Park JY, Lee KU, Kim GS (2006) Homocysteine enhances bone resorption by stimulation of osteoclast formation and activity through increased intracellular ROS generation. J Bone Miner Res 21:1003-1011
15. Vaes BL, Lute C, Blom HJ, Bravenboer N, de Vries TJ, Everts V, Dhonukshe-Rutten RA, Muller M, de Groot LC, Steegenga WT (2009) Vitamin B(12) deficiency stimulates osteoclastogenesis via increased homocysteine and methylmalonic acid. Calcif Tissue Int 84:413-422
16. Herrmann M, Umanskaya N, Wildemann B, Colaianni G, Widmann T, Zallone A, Herrmann W (2008) Stimulation of osteoblast activity by homocysteine. J Cell Mol Med 12:1205-1210
17. Ozdem S, Samanci S, Tasatargil A, Yildiz A, Sadan G, Donmez L, Herrmann M (2007) Experimental hyperhomocysteinemia disturbs bone metabolism in rats. Scand J Clin Lab Invest 67:748-756 (Pubitemid 350034638)
18. Sato Y, Honda Y, Iwamoto J, Kanoko T, Satoh K (2005) Effect of folate and mecobalamin on hip fractures in patients with stroke: a randomized controlled trial. JAMA 293:1082-1088
19. Green TJ, McMahon JA, Skeaff CM, Williams SM, Whiting SJ (2007) Lowering homocysteine with B vitamins has no effect on biomarkers of bone turnover in older persons: a 2-y randomized controlled trial. Am J Clin Nutr 85:460-464
20. Ruan L, Chen W, Srinivasan SR, Xu J, Toprak A, Berenson GS (2009) Plasma homocysteine is adversely associated with glomerular filtration rate in asymptomatic black and white young adults: the Bogalusa heart study. Eur J Epidemiol 24:315-319
21. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH (1993) Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 270:2693-2698
22. Zhang S, Wright JE, Bansal G, Cho P, Uludag H (2005) Cleavage of disulfide-linked fetuin-bisphosphonate conjugates with three physiological thiols. Biomacromolecules 6:2800-2808
23. Melton ME, Kochman ML (1994) Reversal of severe osteoporosis with vitamin B12 and etidronate therapy in a patient with pernicious anemia. Metabolism 43:468-469
24. Bayhan I, Uygur D, Ugurlu N, Ozaksit G (2009) Strontium ranelate decreases plasma homocysteine levels in postmenopausal osteoporotic women. Rheumatol Int 29:263-266
25. Reid IR, Davidson JS, Wattie D, Wu F, Lucas J, Gamble GD, Rutland MD, Cundy T (2004) Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone. Bone 35:224-230